For US Healthcare Professionals Only
Filter
Bimekizumab efficacy on IHS4 response levels and draining tunnels by HS disease duration over 2 years: Data from BE HEARD EXT
Bimekizumab efficacy and safety through 3 years in patients with hidradenitis suppurativa: Results from the phase 3 BE HEARD I&II trials and their open-label extension BE HEARD EXT
Bimekizumab remission and high disease control over 4 years in patients with psoriasis achieving complete skin clearance at Week 16: Results from four phase 3 trials
Bimekizumab safety in patients with psoriasis achieving complete skin clearance: 4-year analysis from 5 phase 3/3b trials
Bimekizumab response in the nail matrix and nail bed through 3 years in patients with moderate to severe plaque psoriasis
Bimekizumab long-term incidence of psoriatic arthritis symptoms and psoriatic arthritis adverse events in patients with psoriasis and risk factors for disease progression
Bimekizumab reduces systemic inflammation and cardiovascular risk gene signatures in psoriatic disease
Bimekizumab efficacy and safety in Chinese patients with moderate to severe plaque psoriasis in the BE SHINING phase 3, multicentre, randomised, double-blinded, placebo-controlled study
Bimekizumab demonstrated long-term efficacy and safety in patients with active psoriatic arthritis who had baseline plaque-type psoriasis and nail involvement: Up to 3-year results from two phase 3 studies
Interim analysis of a European real-world study on the effectiveness and physician satisfaction of bimekizumab treatment in patients with psoriatic arthritis: Insights from France, Germany, Spain, and the United Kingdom
Achieving complete skin clearance was associated with cumulative benefits on disease impact up to 2 years in patients with psoriatic arthritis and psoriasis treated with bimekizumab
Head-to-head study of bimekizumab, an IL-17A/IL-17F inhibitor, and risankizumab, an IL-23 inhibitor, in patients with active psoriatic arthritis: Study design and rationale of BE BOLD, a phase 3b, randomised, parallel-group study
Bimekizumab effect on health-related quality of life and symptoms over 2 years: Data from BE HEARD EXT
Bimekizumab influences the association between HS skin pain severity and health-related quality of life over 2 years: Data from BE HEARD EXT
Bimekizumab maintenance of response over 2 years: Data from BE HEARD EXT
Bimekizumab safety and tolerability in patients with moderate to severe hidradenitis suppurativa: 2-year results from BE HEARD EXT
The journey of patients with hidradenitis suppurativa in Denmark and Norway: Real-world data from the HISREG registry
Bimekizumab impact on hidradenitis suppurativa lesions over 2 years: Data from BE HEARD EXT
Bimekizumab demonstrated sustained efficacy and safety across the full spectrum of axial spondyloarthritis: 3-year results from two phase 3 studies and their open-label extension